These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 9074514)

  • 1. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
    Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
    J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma.
    Tatsumi M; Kitayama H; Sugahara H; Tokita N; Nakamura H; Kanakura Y; Nishimura T
    J Nucl Med; 2001 Apr; 42(4):601-8. PubMed ID: 11337549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
    Bangerter M; Moog F; Buchmann I; Kotzerke J; Griesshammer M; Hafner M; Elsner K; Frickhofen N; Reske SN; Bergmann L
    Ann Oncol; 1998 Oct; 9(10):1117-22. PubMed ID: 9834825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan.
    Hong SP; Hahn JS; Lee JD; Bae SW; Youn MJ
    Yonsei Med J; 2003 Oct; 44(5):779-86. PubMed ID: 14584092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
    Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
    Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.
    Jerusalem G; Warland V; Najjar F; Paulus P; Fassotte MF; Fillet G; Rigo P
    Nucl Med Commun; 1999 Jan; 20(1):13-20. PubMed ID: 9949408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
    Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma.
    de Wit M; Bumann D; Beyer W; Herbst K; Clausen M; Hossfeld DK
    Ann Oncol; 1997; 8 Suppl 1():57-60. PubMed ID: 9187431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
    Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
    Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma.
    Kotzerke J; Guhlmann A; Moog F; Frickhofen N; Reske SN
    Eur J Nucl Med; 1999 Jan; 26(1):31-8. PubMed ID: 9933659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
    Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
    Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
    Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
    J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
    Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
    Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.